Schroder Investment Management Group grew its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 245,726 shares of the company's stock after buying an additional 6,169 shares during the period. Schroder Investment Management Group owned 0.05% of Zoetis worth $40,036,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the stock. Callahan Advisors LLC grew its stake in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after acquiring an additional 6,221 shares during the period. CIBC Asset Management Inc grew its position in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after purchasing an additional 46,050 shares during the period. Pensionfund Sabic grew its position in shares of Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after purchasing an additional 4,000 shares during the period. PFW Advisors LLC acquired a new position in Zoetis in the fourth quarter valued at $1,764,000. Finally, Alberta Investment Management Corp lifted its position in Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock worth $4,904,000 after buying an additional 28,700 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Stock Down 2.5 %
Shares of NYSE ZTS traded down $4.16 on Thursday, hitting $159.34. The company had a trading volume of 3,275,464 shares, compared to its average volume of 2,602,291. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The firm has a market capitalization of $71.35 billion, a P/E ratio of 29.13, a PEG ratio of 2.78 and a beta of 0.94. The business has a 50 day moving average of $166.20 and a two-hundred day moving average of $173.98.
Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.26%. Zoetis's dividend payout ratio is currently 36.56%.
Analyst Upgrades and Downgrades
ZTS has been the subject of a number of research analyst reports. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Piper Sandler lifted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price on the stock. Finally, Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zoetis has an average rating of "Buy" and a consensus price target of $215.90.
View Our Latest Report on ZTS
Insider Buying and Selling at Zoetis
In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 in the last ninety days. Insiders own 0.16% of the company's stock.
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
